Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 451 AL 465

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10.

Percutaneous endoscopic cecostomy (introducer method) in chronic intestinal pseudo-obstruction: Report of two cases and literature review

Küllmer A, Schmidt A, Caca K.

Dig Endosc. 2016 Mar;28(2):210-5. doi: 10.1111/den.12561. Epub 2016 Feb 4.

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Valera E, Spencer B, Masliah E.

Neurotherapeutics. 2016 Jan;13(1):179-89. doi: 10.1007/s13311-015-0397-z.

Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease

Nardin A, Schrepfer E, Ziviani E.

Curr Neuropharmacol. 2016;14(3):250-9. doi: 10.2174/1570159x13666151030104414.

Modulating the Amyloidogenesis of α-Synuclein

Sivanesam K, Andersen NH.

Curr Neuropharmacol. 2016;14(3):226-37. doi: 10.2174/1570159x13666151030103153.

Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson's Disease

Rivero-Ríos P, Madero-Pérez J, Fernández B, Hilfiker S.

Curr Neuropharmacol. 2016;14(3):238-49. doi: 10.2174/1570159x13666151030103027.

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Taymans JM, Greggio E.

Curr Neuropharmacol. 2016;14(3):214-25. doi: 10.2174/1570159x13666151030102847.

Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View

Filograna R, Beltramini M, Bubacco L, Bisaglia M.

Curr Neuropharmacol. 2016;14(3):260-71. doi: 10.2174/1570159x13666151030102718.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Selenium in the Therapy of Neurological Diseases. Where is it Going?

Dominiak A, Wilkaniec A, Wroczyński P, Adamczyk A.

Curr Neuropharmacol. 2016;14(3):282-99. doi: 10.2174/1570159x14666151223100011.

Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis

Negida A, Menshawy A, El Ashal G, Elfouly Y, Hani Y, Hegazy Y, El Ghonimy S, Fouda S, Rashad Y.

CNS Neurol Disord Drug Targets. 2016;15(1):45-53. doi: 10.2174/1871527314666150821103306.

Comparison of Intelligibility Measures for Adults With Parkinson's Disease, Adults With Multiple Sclerosis, and Healthy Controls

Stipancic KL, Tjaden K, Wilding G.

J Speech Lang Hear Res. 2016 Apr 1;59(2):230-8. doi: 10.1044/2015_JSLHR-S-15-0271.

Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants

Sarrafchi A, Bahmani M, Shirzad H, Rafieian-Kopaei M.

Curr Pharm Des. 2016;22(2):238-46. doi: 10.2174/1381612822666151112151653.

Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors

Orhan IE.

Curr Pharm Des. 2016;22(3):268-76. doi: 10.2174/1381612822666151112150612.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias